Verona Pharma plc (NASDAQ:VRNA) Q3 2024 Earnings Call Transcript
Operator: Good morning, everyone, and welcome to Verona Pharma's Third Quarter 2024 Financial Results and Operating Highlights Conference Call.
Verona Pharma Plc (VRNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 6,315,933 | $181,709,392 | +160% | 3.84% |
| 2. | RA Capital Management Peter Kolchinsky | 5,009,653 | $144,127,717 | -35% | 1.66% |
| 3. | Maverick Capital Lee Ainslie | 4,215,973 | $121,293,543 | +37% | 2.36% |
| 4. | Vivo Capital Albert Cha And Frank Kung | 3,549,758 | $102,126,538 | 8.45% | |
| 5. | Deep Track Capital David Kroin | 3,180,025 | $91,489,319 | -21% | 2.9% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.44 | 20,000 | Director | 940,003 | 2024-11-18 | Filing | |
| $4.80 | 39,360 | Director | 920,003 | 2024-11-06 | Filing | |
| $4.74 | 41,880 | Director | 41,880 | 2024-11-06 | Filing | |
| $2.87 | 36,000 | Director | 880,643 | 2024-08-12 | Filing | |
| $1.84 | 33,736 | Director | 144,800 | 2023-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.00 | 2,400 | Officer, Director | 15,202,352 | 2024-11-11 | Filing | |
| $5.00 | 2,400 | Officer | 14,291,336 | 2024-11-11 | Filing | |
| $4.39 | 94,144 | Officer, Director | 15,204,752 | 2024-11-04 | Filing | |
| $4.38 | 46,888 | Officer, Director | 15,298,896 | 2024-11-01 | Filing | |
| $4.39 | 80,784 | Officer | 14,293,736 | 2024-11-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,108,563 | $111,024,890 | 7.39% | |
| 2. | 4,902,377 | $97,459,255 | 0% | |
| 3. | 3,783,994 | $75,225,800 | 0.01% | |
| 4. | 3,014,349 | $59,925,258 | 3.2% | |
| 5. | 2,493,530 | $49,571,376 | 0.12% |
News See All
Verona Pharma plc (NASDAQ:VRNA) Q2 2024 Earnings Call Transcript
Operator: Welcome to Verona Pharma’s Second Quarter 2024 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode.
Top 10 Holdings of Caligan Partners
Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.
Verona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript
Operator: Hello, and welcome to Verona Pharma's First Quarter 2024 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode.
Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript
Verona Pharma plc beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23.
11 Best Undervalued UK Stocks To Buy Now
In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now.
Verona Pharma plc (NASDAQ:VRNA) Q3 2023 Earnings Call Transcript
Operator: Welcome to Verona Pharma's Third Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode.
12 Best High Risk High Reward Stocks To Buy Now
In this piece, we will take a look at the 12 best high risk high reward stocks to buy now.
Verona Pharma plc (NASDAQ:VRNA) Q2 2023 Earnings Call Transcript
Operator: Welcome to Verona Pharma Second Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time all participants are in listen-only mode.
Verona Pharma plc (NASDAQ:VRNA) Q1 2023 Earnings Call Transcript
Operator: Good morning. Welcome to Verona Pharma's First Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a mode.
Billionaire Hedge Funds
